EDIT - Editas Medicine - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

EDIT is currently covered by 15 analysts with an average price target of $4.57. This is a potential upside of $1.57 (52.33%) from yesterday's end of day stock price of $3.

Editas Medicine's activity chart (see below) currently has 118 price targets and 121 ratings on display. The stock rating distribution of EDIT is 51.28% BUY, 43.59% HOLD and 5.13% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 47.48% with an average time for these price targets to be met of 134.84 days.

Highest price target for EDIT is $6, Lowest price target is $1, average price target is $6.2.

Most recent stock forecast was given by YANAN ZHU from WELLS FARGO on 03-Sep-2025. First documented stock forecast 29-Feb-2016.

Currently out of the existing stock ratings of EDIT, 20 are a BUY (51.28%), 17 are a HOLD (43.59%), 2 are a SELL (5.13%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$4

$1.31 (48.70%)

$3

15 days ago
(03-Sep-2025)

3/9 (33.33%)

$1.5 (60.00%)

56

Buy

$6

$3.31 (123.05%)

$4

1 months 5 days ago
(13-Aug-2025)

1/7 (14.29%)

$2.92 (94.81%)

26

Sell

$9

9 months 2 days ago
(16-Dec-2024)

2/2 (100%)

$0.14 (1.58%)

9

Buy

$5

$2.31 (85.87%)

$7

9 months 2 days ago
(16-Dec-2024)

2/5 (40%)

$3.52 (237.84%)

7

$3

$0.31 (11.52%)

$5

9 months 5 days ago
(13-Dec-2024)

8/12 (66.67%)

$1.56 (108.33%)

200

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is EDIT (Editas Medicine) average time for price targets to be met?

On average it took 134.84 days on average for the stock forecasts to be realized with a an average price target met ratio 47.48

Which analyst has the current highest performing score on EDIT (Editas Medicine) with a proven track record?

STEVEN SEEDHOUSE

Which analyst has the most public recommendations on EDIT (Editas Medicine)?

Steven Seedhouse works at RAYMOND JAMES and has 7 price targets and 5 ratings on EDIT

Which analyst is the currently most bullish on EDIT (Editas Medicine)?

Cory Kasimov with highest potential upside - $21.82

Which analyst is the currently most reserved on EDIT (Editas Medicine)?

Greg Harrison with lowest potential downside - -$1.69

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?